Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

CXCL12 retargeting of an adenovirus vector to cancer cells using a bispecific adapter.

Bhatia S, O'Bryan SM, Rivera AA, Curiel DT, Mathis JM.

Oncolytic Virother. 2016 Nov 11;5:99-113. eCollection 2016.

2.

Puf4 regulates both splicing and decay of HXL1 mRNA encoding the unfolded protein response transcription factor in Cryptococcus neoformans.

Glazier VE, Kaur JN, Brown NT, Rivera AA, Panepinto JC.

Eukaryot Cell. 2015 Apr;14(4):385-95. doi: 10.1128/EC.00273-14. Epub 2015 Feb 13.

3.

Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: a population and clonal analysis.

Barnard RJ, McHale CM, Newhard W, Cheney CA, Graham DJ, Himmelberger AL, Strizki J, Hwang PM, Rivera AA, Reeves JD, Nickle D, Dinubile MJ, Hazuda DJ, Mobashery N.

Virology. 2013 Sep 1;443(2):278-84. doi: 10.1016/j.virol.2013.05.013. Epub 2013 Jun 10.

4.

[Socio-demographic Characterization of Psychosexual Development and Crime in Men Convicted of Sexual Crimes Imprisoned in the Manizales Penitentiary Center].

Rivera AA, Ramírez MC, Montoya DO, Quiroz G.

Rev Colomb Psiquiatr. 2013 Mar;42(1):51-62. doi: 10.1016/S0034-7450(14)60086-X. Epub 2014 May 10. Spanish.

PMID:
26572712
5.

Expression of osteoprotegerin from a replicating adenovirus inhibits the progression of prostate cancer bone metastases in a murine model.

Cody JJ, Rivera AA, Lyons GR, Yang SW, Wang M, Ashley JW, Meleth S, Feng X, Siegal GP, Douglas JT.

Lab Invest. 2013 Mar;93(3):268-78. doi: 10.1038/labinvest.2012.179. Epub 2013 Jan 28.

6.

A tumor-stroma targeted oncolytic adenovirus replicated in human ovary cancer samples and inhibited growth of disseminated solid tumors in mice.

Lopez MV, Rivera AA, Viale DL, Benedetti L, Cuneo N, Kimball KJ, Wang M, Douglas JT, Zhu ZB, Bravo AI, Gidekel M, Alvarez RD, Curiel DT, Podhajcer OL.

Mol Ther. 2012 Dec;20(12):2222-33. doi: 10.1038/mt.2012.147. Epub 2012 Sep 4.

7.

[The relationship between income and children's habitual consumption of β-carotene, vitamin C and vitamin E in food].

de Paiva-Bandeira GT, Rios-Asciutti LS, Rivera AA, Rodrigues-Gonçalves Mda C, Pordeus-de-Lima RC, Marinho-Albuquerque T, Marcos-de-Morais R, de Toledo-Vianna RP, Farias-de-Oliveira A, Teixeira-Lima R, de Carvalho-Costa MJ.

Rev Salud Publica (Bogota). 2011 Jun;13(3):386-97. Portuguese.

8.

Conditionally replicating adenovirus expressing TIMP2 increases survival in a mouse model of disseminated ovarian cancer.

Yang SW, Chanda D, Cody JJ, Rivera AA, Waehler R, Siegal GP, Douglas JT, Ponnazhagan S.

PLoS One. 2011;6(10):e25131. doi: 10.1371/journal.pone.0025131. Epub 2011 Oct 12.

9.

A simplified method for the generation of human osteoclasts in vitro.

Cody JJ, Rivera AA, Liu J, Liu JM, Douglas JT, Feng X.

Int J Biochem Mol Biol. 2011;2(2):183-189. Epub 2011 Apr 23.

10.

Increased plasma chymase concentration and mast cell chymase expression in venous neointimal lesions of patients with CKD and ESRD.

Wasse H, Rivera AA, Huang R, Martinson DE, Long Q, McKinnon W, Naqvi N, Husain A.

Semin Dial. 2011 Nov-Dec;24(6):688-93. doi: 10.1111/j.1525-139X.2011.00921.x. Epub 2011 Jul 22.

11.

Conditionally replicating adenovirus expressing TIMP2 for ovarian cancer therapy.

Yang SW, Cody JJ, Rivera AA, Waehler R, Wang M, Kimball KJ, Alvarez RA, Siegal GP, Douglas JT, Ponnazhagan S.

Clin Cancer Res. 2011 Feb 1;17(3):538-49. doi: 10.1158/1078-0432.CCR-10-1628. Epub 2010 Nov 29.

12.

Arming a replicating adenovirus with osteoprotegerin reduces the tumor burden in a murine model of osteolytic bone metastases of breast cancer.

Cody JJ, Rivera AA, Lyons GR, Yang SW, Wang M, Sarver DB, Wang D, Selander KS, Kuo HC, Meleth S, Feng X, Siegal GP, Douglas JT.

Cancer Gene Ther. 2010 Dec;17(12):893-905. doi: 10.1038/cgt.2010.47. Epub 2010 Aug 27. Erratum in: Cancer Gene Ther. 2010 Dec;17(12):906. Siegall, G P [corrected to Siegal, G P].

13.

Substitution of adenovirus serotype 3 hexon onto a serotype 5 oncolytic adenovirus reduces factor X binding, decreases liver tropism, and improves antitumor efficacy.

Short JJ, Rivera AA, Wu H, Walter MR, Yamamoto M, Mathis JM, Curiel DT.

Mol Cancer Ther. 2010 Sep;9(9):2536-44. doi: 10.1158/1535-7163.MCT-10-0332. Epub 2010 Aug 24.

14.

Ex vivo transfer of the Hoxc-8-interacting domain of Smad1 by a tropism-modified adenoviral vector results in efficient bone formation in a rabbit model of spinal fusion.

Douglas JT, Rivera AA, Lyons GR, Lott PF, Wang D, Zayzafoon M, Siegal GP, Cao X, Theiss SM.

J Spinal Disord Tech. 2010 Feb;23(1):63-73. doi: 10.1097/BSD.0b013e318193b693.

15.

Novel infectivity-enhanced oncolytic adenovirus with a capsid-incorporated dual-imaging moiety for monitoring virotherapy in ovarian cancer.

Kimball KJ, Rivera AA, Zinn KR, Icyuz M, Saini V, Li J, Zhu ZB, Siegal GP, Douglas JT, Curiel DT, Alvarez RD, Borovjagin AV.

Mol Imaging. 2009 Sep-Oct;8(5):264-77.

16.

Promotion of incisional wound repair by human mesenchymal stem cell transplantation.

Stoff A, Rivera AA, Sanjib Banerjee N, Moore ST, Michael Numnum T, Espinosa-de-Los-Monteros A, Richter DF, Siegal GP, Chow LT, Feldman D, Vasconez LO, Michael Mathis J, Stoff-Khalili MA, Curiel DT.

Exp Dermatol. 2009 Apr;18(4):362-9. doi: 10.1111/j.1600-0625.2008.00792.x. Epub 2008 Sep 18.

17.

Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach.

Matthews QL, Yang P, Wu Q, Belousova N, Rivera AA, Stoff-Khalili MA, Waehler R, Hsu HC, Li Z, Li J, Mountz JD, Wu H, Curiel DT.

Virol J. 2008 Aug 21;5:98. doi: 10.1186/1743-422X-5-98.

18.

Evaluation of E1A double mutant oncolytic adenovectors in anti-glioma gene therapy.

Ulasov IV, Tyler MA, Rivera AA, Nettlebeck DM, Douglas JT, Lesniak MS.

J Med Virol. 2008 Sep;80(9):1595-603. doi: 10.1002/jmv.21264.

19.

Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma.

Sonabend AM, Ulasov IV, Tyler MA, Rivera AA, Mathis JM, Lesniak MS.

Stem Cells. 2008 Mar;26(3):831-41. doi: 10.1634/stemcells.2007-0758. Epub 2008 Jan 10.

20.

Targeting of a conditionally replicative adenovirus agent to human squamous cell carcinomas of the head and neck.

Zhu ZB, Mathis JM, Makhija SK, Lu B, Wang M, Ji S, Rivera AA, Rosenthal EL, Siegal GP, Curiel DT.

Int J Oncol. 2007 Nov;31(5):1213-22.

PMID:
17912450
21.

An oncolytic adenoviral vector carrying the tyrosinase promoter for glioma gene therapy.

Ulasov IV, Rivera AA, Nettelbeck DM, Rivera LB, Mathis JM, Sonabend AM, Tyler M, Wang M, Douglas JT, Lesniak MS.

Int J Oncol. 2007 Nov;31(5):1177-85.

PMID:
17912445
22.

Targeting adenovirus to CD80 and CD86 receptors increases gene transfer efficiency to malignant glioma cells.

Ulasov IV, Rivera AA, Han Y, Curiel DT, Zhu ZB, Lesniak MS.

J Neurosurg. 2007 Sep;107(3):617-27.

PMID:
17886563
23.

Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma.

Ulasov IV, Zhu ZB, Tyler MA, Han Y, Rivera AA, Khramtsov A, Curiel DT, Lesniak MS.

Hum Gene Ther. 2007 Jul;18(7):589-602.

PMID:
17630837
24.

Cancer-specific targeting of a conditionally replicative adenovirus using mRNA translational control.

Stoff-Khalili MA, Rivera AA, Nedeljkovic-Kurepa A, DeBenedetti A, Li XL, Odaka Y, Podduturi J, Sibley DA, Siegal GP, Stoff A, Young S, Zhu ZB, Curiel DT, Mathis JM.

Breast Cancer Res Treat. 2008 Mar;108(1):43-55. Epub 2007 May 17.

25.

Comparative evaluation of survivin, midkine and CXCR4 promoters for transcriptional targeting of glioma gene therapy.

Ulasov IV, Rivera AA, Sonabend AM, Rivera LB, Wang M, Zhu ZB, Lesniak MS.

Cancer Biol Ther. 2007 May;6(5):679-85. Epub 2007 Feb 3.

PMID:
17404502
26.

Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma.

Stoff-Khalili MA, Rivera AA, Mathis JM, Banerjee NS, Moon AS, Hess A, Rocconi RP, Numnum TM, Everts M, Chow LT, Douglas JT, Siegal GP, Zhu ZB, Bender HG, Dall P, Stoff A, Pereboeva L, Curiel DT.

Breast Cancer Res Treat. 2007 Oct;105(2):157-67. Epub 2007 Jan 13.

PMID:
17221158
27.

Effect of adenoviral mediated overexpression of fibromodulin on human dermal fibroblasts and scar formation in full-thickness incisional wounds.

Stoff A, Rivera AA, Mathis JM, Moore ST, Banerjee NS, Everts M, Espinosa-de-los-Monteros A, Novak Z, Vasconez LO, Broker TR, Richter DF, Feldman D, Siegal GP, Stoff-Khalili MA, Curiel DT.

J Mol Med (Berl). 2007 May;85(5):481-96. Epub 2007 Jan 12.

PMID:
17219096
28.

Treatment of ovarian cancer with a novel dual targeted conditionally replicative adenovirus (CRAd).

Rocconi RP, Zhu ZB, Stoff-Khalili M, Rivera AA, Lu B, Wang M, Alvarez RD, Curiel DT, Makhija SK.

Gynecol Oncol. 2007 Apr;105(1):113-21. Epub 2006 Dec 14.

PMID:
17173958
29.

Combining high selectivity of replication via CXCR4 promoter with fiber chimerism for effective adenoviral oncolysis in breast cancer.

Stoff-Khalili MA, Rivera AA, Stoff A, Michael Mathis J, Rocconi RP, Matthews QL, Numnum MT, Herrmann I, Dall P, Eckhoff DE, Douglas JT, Siegal GP, Zhu ZB, Curiel DT.

Int J Cancer. 2007 Feb 15;120(4):935-41.

30.

Targeting lung cancer using an infectivity enhanced CXCR4-CRAd.

Zhu ZB, Rivera AA, Makhija SK, Lu B, Wang M, Izumi M, Cerfolio RJ, Stoff-Khalili MA, Zhou F, Takayama K, Siegal GP, Curiel DT.

Lung Cancer. 2007 Feb;55(2):145-56. Epub 2006 Nov 17.

31.

Tissue inhibitor of metalloproteinases-2 improves antitumor efficacy of a replicating adenovirus in vivo.

Kim MH, Bodenstine TM, Sumerel LA, Rivera AA, Baker AH, Douglas JT.

Cancer Biol Ther. 2006 Dec;5(12):1647-53. Epub 2006 Dec 7.

32.

Survivin promoter-based conditionally replicative adenoviruses target cholangiocarcinoma.

Zhu ZB, Chen Y, Makhija SK, Lu B, Wang M, Rivera AA, Yamamoto M, Wang S, Siegal GP, Curiel DT, McDonald JM.

Int J Oncol. 2006 Nov;29(5):1319-29.

PMID:
17016667
33.

Strategies to enhance transductional efficiency of adenoviral-based gene transfer to primary human fibroblasts and keratinocytes as a platform in dermal wounds.

Stoff A, Rivera AA, Banerjee NS, Mathis JM, Espinosa-de-los-Monteros A, Le LP, De la Torre JI, Vasconez LO, Broker TR, Richter DF, Stoff-Khalili MA, Curiel DT.

Wound Repair Regen. 2006 Sep-Oct;14(5):608-17.

34.

Icodextrin enhances survival in an intraperitoneal ovarian cancer murine model utilizing gene therapy.

Rocconi RP, Numnum MT, Zhu ZB, Lu B, Wang M, Rivera AA, Stoff-Khalili M, Alvarez RD, Curiel DT, Makhija S.

Gynecol Oncol. 2006 Dec;103(3):985-9. Epub 2006 Jul 20.

PMID:
16857247
35.

The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma.

Van Houdt WJ, Haviv YS, Lu B, Wang M, Rivera AA, Ulasov IV, Lamfers ML, Rein D, Lesniak MS, Siegal GP, Dirven CM, Curiel DT, Zhu ZB.

J Neurosurg. 2006 Apr;104(4):583-92.

PMID:
16619663
36.

Preclinical evaluation of transcriptional targeting strategies for carcinoma of the breast in a tissue slice model system.

Stoff-Khalili MA, Stoff A, Rivera AA, Banerjee NS, Everts M, Young S, Siegal GP, Richter DF, Wang M, Dall P, Mathis JM, Zhu ZB, Curiel DT.

Breast Cancer Res. 2005;7(6):R1141-52. Epub 2005 Nov 16.

37.

Employment of liver tissue slice analysis to assay hepatotoxicity linked to replicative and nonreplicative adenoviral agents.

Stoff-Khalili MA, Rivera AA, Le LP, Stoff A, Everts M, Contreras JL, Chen D, Teng L, Rots MG, Haisma HJ, Rocconi RP, Bauerschmitz GJ, Rein DT, Yamamoto M, Siegal GP, Dall P, Michael Mathis J, Curiel DT.

Cancer Gene Ther. 2006 Jun;13(6):606-18.

PMID:
16410819
38.

Infectivity enhancement for adenoviral transduction of canine osteosarcoma cells.

Le LP, Rivera AA, Glasgow JN, Ternovoi VV, Wu H, Wang M, Smith BF, Siegal GP, Curiel DT.

Gene Ther. 2006 Mar;13(5):389-99.

PMID:
16292351
39.

Gene transfer to carcinoma of the breast with fiber-modified adenoviral vectors in a tissue slice model system.

Stoff-Khalili MA, Stoff A, Rivera AA, Mathis JM, Everts M, Wang M, Kawakami Y, Waehler R, Mathews QL, Yamamoto M, Rocconi RP, Siegal GP, Richter DF, Dall P, Zhu ZB, Curiel DT.

Cancer Biol Ther. 2005 Nov;4(11):1203-10. Epub 2005 Nov 8.

PMID:
16177567
40.

A human adenoviral vector with a chimeric fiber from canine adenovirus type 1 results in novel expanded tropism for cancer gene therapy.

Stoff-Khalili MA, Rivera AA, Glasgow JN, Le LP, Stoff A, Everts M, Tsuruta Y, Kawakami Y, Bauerschmitz GJ, Mathis JM, Pereboeva L, Seigal GP, Dall P, Curiel DT.

Gene Ther. 2005 Dec;12(23):1696-706.

PMID:
16034451
41.

Incorporating the survivin promoter in an infectivity enhanced CRAd-analysis of oncolysis and anti-tumor effects in vitro and in vivo.

Zhu ZB, Makhija SK, Lu B, Wang M, Rivera AA, Kim-Park S, Ulasov IV, Zhou F, Alvarez RD, Siegal GP, Curiel DT.

Int J Oncol. 2005 Jul;27(1):237-46.

PMID:
15942665
42.

Evaluation of tumor-specific promoter activities in melanoma.

Lu B, Makhija SK, Nettelbeck DM, Rivera AA, Wang M, Komarova S, Zhou F, Yamamoto M, Haisma HJ, Alvarez RD, Curiel DT, Zhu ZB.

Gene Ther. 2005 Feb;12(4):330-8.

PMID:
15696177
43.

Combining high selectivity of replication with fiber chimerism for effective adenoviral oncolysis of CAR-negative melanoma cells.

Rivera AA, Davydova J, Schierer S, Wang M, Krasnykh V, Yamamoto M, Curiel DT, Nettelbeck DM.

Gene Ther. 2004 Dec;11(23):1694-702.

PMID:
15496964
44.

Employment of microarray analysis to characterize biologic differences associated with tropism-modified adenoviral vectors: utilization of non-native cellular entry pathways.

Volk AL, Rivera AA, Page GP, Salazar-Gonzalez JF, Nettelbeck DM, Matthews QL, Curiel DT.

Cancer Gene Ther. 2005 Feb;12(2):162-74.

PMID:
15375380
45.

Transport across a polarized monolayer of Caco-2 cells by transferrin receptor-mediated adenovirus transcytosis.

Zhu ZB, Makhija SK, Lu B, Wang M, Rivera AA, Preuss M, Zhou F, Siegal GP, Alvarez RD, Curiel DT.

Virology. 2004 Jul 20;325(1):116-28.

46.

Analyses of melanoma-targeted oncolytic adenoviruses with tyrosinase enhancer/promoter-driven E1A, E4, or both in submerged cells and organotypic cultures.

Banerjee NS, Rivera AA, Wang M, Chow LT, Broker TR, Curiel DT, Nettelbeck DM.

Mol Cancer Ther. 2004 Apr;3(4):437-49.

47.

Transcriptional targeting of adenoviral vector through the CXCR4 tumor-specific promoter.

Zhu ZB, Makhija SK, Lu B, Wang M, Kaliberova L, Liu B, Rivera AA, Nettelbeck DM, Mahasreshti PJ, Leath CA 3rd, Yamamoto M, Alvarez RD, Curiel DT.

Gene Ther. 2004 Apr;11(7):645-8. Erratum in: Gene Ther. 2006 Feb;13(4):374. Yamaoto, M [corrected to Yamamoto, M].

PMID:
15029227
48.

Transcriptional targeting of tumors with a novel tumor-specific survivin promoter.

Zhu ZB, Makhija SK, Lu B, Wang M, Kaliberova L, Liu B, Rivera AA, Nettelbeck DM, Mahasreshti PJ, Leath CA, Barker S, Yamaoto M, Li F, Alvarez RD, Curiel DT.

Cancer Gene Ther. 2004 Apr;11(4):256-62.

PMID:
15017380
49.
50.

Retargeting of adenoviral infection to melanoma: combining genetic ablation of native tropism with a recombinant bispecific single-chain diabody (scDb) adapter that binds to fiber knob and HMWMAA.

Nettelbeck DM, Rivera AA, Kupsch J, Dieckmann D, Douglas JT, Kontermann RE, Alemany R, Curiel DT.

Int J Cancer. 2004 Jan 1;108(1):136-45.

Supplemental Content

Loading ...
Support Center